Why did teriparatide take so long to develop?

PTH had been known since the early 1900s, but its bone-building potential wasn't fully characterised until animal studies in the 1980s–90s. Preclinical toxicology and two decades of mechanism research were needed before the FDA considered human trials feasible. The Phase 3 fracture trial itself took 21 months, and additional post-approval studies extended the timeline. Novel mechanisms require extensive evidence.

What made the Phase 3 fracture trial so important?

It was the first time a PTH analog demonstrated fracture risk reduction in humans—the gold-standard outcome for osteoporosis therapy. Prior treatments showed bone density gains, but not necessarily fewer fractures. This trial proved teriparatide's clinical benefit and became the cornerstone of regulatory approval across all regions.

Why does teriparatide have an osteosarcoma warning?

[Rat studies at high doses showed increased osteosarcoma risk](https://pubmed.ncbi.nlm.nih.gov/15090512). Although human surveillance has not identified excess risk at approved doses over 20+ years, the FDA requires a REMS and contraindication in patients with osteosarcoma history or unexplained elevated alkaline phosphatase. This reflects a precautionary approach to a novel agent.

How many trials have tested teriparatide?

Over 176 clinical trials have investigated teriparatide across osteoporosis, diabetes, fracture healing, and other indications. This extensive evidence base supports its approved uses and has explored potential applications beyond the original FDA indication.

Are there biosimilars of teriparatide available?

Yes. As teriparatide's original patents expired, biosimilar versions have been approved or are in development globally. These are expected to increase access and reduce costs, similar to insulin and other biologic therapies.

Teriparatide Regulatory History: From Lab to FDA Approval

Teriparatide is an FDA-approved parathyroid hormone analog that represents a paradigm shift in osteoporosis treatment. Unlike bone-resorption inhibitors, teriparatide actively stimulates bone formation—a mechanism that took decades of research to prove safe and effective in humans. Approved by the FDA in 2002, it's now authorised across the US, EU, and Canada, backed by over 176 clinical trials. This timeline traces teriparatide's journey from laboratory discovery through regulatory approval and into current clinical use, showing how rigorous evidence builds confidence in a novel therapeutic approach.

The Discovery Era: 1970s–1990s

Teriparatide's story begins with a fundamental question: could parathyroid hormone (PTH) itself be used as a medicine? Scientists discovered that PTH, a naturally occurring hormone that regulates calcium and phosphate metabolism, had a surprising property—when given as intermittent injections rather than continuous infusions, it stimulated bone formation instead of resorption.

Pioneering animal studies in the 1980s and 1990s demonstrated that PTH fragments could increase bone mass, contradicting conventional wisdom that PTH only caused bone loss. Researchers at Indiana University and other institutions synthesised teriparatide, the active 34-amino-acid fragment of human PTH (PTH 1-34), and began exploring its potential in preclinical models.

This discovery was revolutionary because it offered a fundamentally different strategy from existing osteoporosis treatments, which primarily slowed bone loss through suppression of osteoclast activity. Teriparatide promised to actively build bone by stimulating osteoblasts—the cells responsible for new bone formation.

Preclinical Development and IND Application (1990s)

Throughout the 1990s, Eli Lilly and Co. (the pharmaceutical partner driving development) conducted extensive animal toxicology and pharmacology studies. These preclinical trials were essential to demonstrate safety and biological plausibility before human testing could begin.

By the late 1990s, the company had assembled sufficient evidence to submit an Investigational New Drug (IND) application to the FDA, clearing the pathway for Phase 1 human studies. The IND process requires detailed chemistry, manufacturing, and controls data alongside preclinical safety data—a critical regulatory checkpoint.

Phase 1 & 2 Clinical Trials (1997–2000)

Early human studies focused on safety, tolerability, and pharmacokinetics. Phase 1 trials established that subcutaneous injections of teriparatide were well-tolerated and rapidly absorbed, with Peak serum levels occurring within 30 minutes of injection.

Phase 2 trials in postmenopausal women with osteoporosis (the target population) demonstrated proof-of-concept: teriparatide increased bone mineral density (BMD) at the lumbar spine and hip compared to placebo. Biochemical markers of bone turnover—P1NP (procollagen type 1 N-terminal propeptide) and CTX (C-terminal telopeptide of type 1 collagen)—showed the expected dual response: increased bone formation markers coupled with modest increases in bone resorption markers.

These trials generated significant excitement in the osteoporosis research community because they showed a new mechanism at work in real patients.

Phase 3: The Pivotal Fracture Reduction Trial (2000–2001)

The critical test came in Phase 3—the "Fracture Prevention Trial" (FPT), a landmark study that enrolled over 1,600 postmenopausal women with osteoporosis and prior vertebral fractures. This 21-month randomised controlled trial compared daily subcutaneous teriparatide injections (20 µg and 40 µg doses) against placebo.

The FPT demonstrated that teriparatide reduced the risk of new vertebral fractures by 65% (at 20 µg) and 69% (at 40 µg) compared to placebo. This was a landmark finding: the first time a PTH analog had shown fracture risk reduction in humans. Non-vertebral fracture risk was also reduced, though the sample size limited statistical power for this secondary endpoint.

Bone mineral density increased significantly at the lumbar spine (by 9–13% over 21 months) and at the femoral neck, further validating the bone-building mechanism.

FDA Review and Approval (2002)

Based on the Phase 3 data, Eli Lilly submitted a Biologics License Application (BLA) to the FDA's Center for Drug Evaluation and Research (CDER) in late 2001. The BLA package included:

Manufacturing data on the recombinant human PTH 1-34 (teriparatide)
Complete preclinical toxicology and pharmacology
Phase 1, 2, and 3 clinical data
Safety and efficacy summaries across the development program

The FDA approved teriparatide (marketed as Forteo®) on 2 October 2002 for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture. This was the first PTH analog approved for osteoporosis—a genuine innovation in the therapeutic landscape, which until then had been dominated by bisphosphonates and hormone replacement therapy.

The FDA approval was based primarily on the fracture reduction data and bone density improvements, though long-term safety monitoring was built into post-approval surveillance plans due to teriparatide's novel mechanism and the theoretical concern about bone tumours (explored below).

Post-Approval Studies and Label Updates (2002–Present)

After FDA approval, the regulatory and clinical emphasis shifted to long-term safety and head-to-head efficacy comparisons.

The H-Trial Extension

Eli Lilly conducted an open-label extension of the FPT, enrolling many original participants for up to 2 additional years of teriparatide treatment (total exposure up to 4 years). This extension study confirmed sustained increases in bone density and continued fracture risk reduction, with a safety profile consistent with Phase 3.

Combination and Sequential Therapy Studies

Clinicians and researchers asked: what happens when teriparatide is followed by a bisphosphonate, or vice versa? Several trials examined sequential therapy, showing that teriparatide followed by alendronate (a bisphosphonate) maintained or further improved bone density. This opened new treatment pathways for severe osteoporosis.

The Osteosarcoma Question

One early regulatory concern was the potential for osteosarcoma (bone cancer) risk. Preclinical studies in rats given very high doses of PTH analogs showed increased osteosarcoma incidence. To address this, the FDA required a Risk Evaluation and Mitigation Strategy (REMS) and established a contraindication for patients with a history of osteosarcoma or unexplained elevated alkaline phosphatase. Post-approval surveillance and long-term observational cohorts have not identified excess osteosarcoma risk in humans at approved doses, but monitoring continues.

International Regulatory Approvals

European Medicines Agency (EMA)

The EMA approved teriparatide (Forsteo®) in the EU in September 2003, following a similar review of the Phase 3 data and manufacturing quality. The European approval covered postmenopausal women with osteoporosis at high risk of fracture, consistent with the FDA label.

Health Canada

Health Canada approved teriparatide in 2004 under a similar regulatory pathway, further expanding access to this therapy in North America.

Current Status: Approved, Widely Used

As of 2024, teriparatide remains one of the few bone-building (anabolic) agents available for osteoporosis. Over 176 clinical trials have been conducted across multiple indications and populations, supporting its use in:

Postmenopausal osteoporosis (FDA-approved)
Male osteoporosis (FDA-approved)
Glucocorticoid-induced osteoporosis (FDA-approved)
Severe or refractory osteoporosis (clinical practice)

Related Compounds and the Broader PTH Landscape

Teriparatide's success paved the way for related compounds. Abaloparatide, another PTH-related peptide agonist, was approved by the FDA in 2017 and shows similar or superior fracture reduction in some trials. Romosozumab, a sclerostin monoclonal antibody that works through a different mechanism (enhanced Wnt signaling in osteoblasts), was approved in 2019 as another anabolic approach.

These successors validated the "bone-building" paradigm that teriparatide established.

Generic and Biosimilar Competition

Teriparatide's patent protection has expired in most markets, opening the door to biosimilars. Several biosimilar versions have been approved or are in development globally, potentially lowering costs and increasing access, particularly in developing regions.

Key Regulatory Takeaways

Teriparatide's regulatory journey illustrates several important principles:

Novel Mechanisms Require Robust Evidence: The FDA and EMA demanded Phase 3 fracture-reduction data—not just bone density improvements—before approving a first-in-class PTH analog.
Preclinical Safety Signals Drive Long-term Monitoring: The osteosarcoma signal in rat studies led to REMS and contraindications, demonstrating how preclinical findings shape post-approval surveillance.
International Harmonisation: FDA, EMA, and Health Canada approvals occurred within months of each other, reflecting alignment in safety and efficacy standards.
Extended Evidence: Post-approval open-label extensions and real-world observational studies continued to build the safety database, important for a novel agent.

Today, teriparatide is recognised globally as a cornerstone therapy for osteoporosis, particularly in severe, refractory cases or when rapid bone formation is needed. Its regulatory history remains a case study in how rigorous clinical trial design and long-term safety surveillance can introduce genuinely novel therapeutic approaches into mainstream practice.

Teriparatide Regulatory History: The Path to Approval